Product: GFAP Antibody
Catalog: DF6040
Description: Rabbit polyclonal antibody to GFAP
Application: WB IHC IF/ICC
Cited expt.: WB, IHC, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Horse, Rabbit, Chicken
Mol.Wt.: 45-50kDa; 50kD(Calculated).
Uniprot: P14136
RRID: AB_2838012

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:500-1:1000
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Bovine(100%), Horse(100%), Rabbit(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
GFAP Antibody detects endogenous levels of total GFAP.
RRID:
AB_2838012
Cite Format: Affinity Biosciences Cat# DF6040, RRID:AB_2838012.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

wu:fb34h11; ALXDRD; cb345; etID36982.3; FLJ42474; FLJ45472; GFAP; GFAP_HUMAN; gfapl; Glial fibrillary acidic protein; Intermediate filament protein; wu:fk42c12; xx:af506734; zgc:110485;

Immunogens

Immunogen:

A synthesized peptide derived from human GFAP, corresponding to a region within C-terminal amino acids.

Uniprot:
Gene(ID):
Expression:
P14136 GFAP_HUMAN:

Expressed in cells lacking fibronectin.

Description:
The cytoskeleton consists of three types of cytosolic fibers: microfilaments (actin filaments), intermediate filaments, and microtubules. Major types of intermediate filaments are specifically expressed in particular cell types: cytokeratins in epithelial cells, glial fibrillary acidic protein (GFAP) in glial cells, desmin in skeletal, visceral, and certain vascular smooth muscle cells, vimentin in cells of mesenchymal origin, and neurofilaments in neurons. GFAP and vimentin form intermediate filaments in astroglial cells and modulate their motility and shape (1). In particular, vimentin filaments are present at early developmental stages, while GFAP filaments are characteristic of differentiated and mature brain astrocytes. Thus, GFAP is commonly used as a marker for intracranial and intraspinal tumors arising from astrocytes (2). In addition, GFAP intermediate filaments are also present in non-myelin-forming Schwann cells in the peripheral nervous system (3).
Sequence:
MERRRITSAARRSYVSSGEMMVGGLAPGRRLGPGTRLSLARMPPPLPTRVDFSLAGALNAGFKETRASERAEMMELNDRFASYIEKVRFLEQQNKALAAELNQLRAKEPTKLADVYQAELRELRLRLDQLTANSARLEVERDNLAQDLATVRQKLQDETNLRLEAENNLAAYRQEADEATLARLDLERKIESLEEEIRFLRKIHEEEVRELQEQLARQQVHVELDVAKPDLTAALKEIRTQYEAMASSNMHEAEEWYRSKFADLTDAAARNAELLRQAKHEANDYRRQLQSLTCDLESLRGTNESLERQMREQEERHVREAASYQEALARLEEEGQSLKDEMARHLQEYQDLLNVKLALDIEIATYRKLLEGEENRITIPVQTFSNLQIRETSLDTKSVSEGHLKRNIVVKTVEMRDGEVIKESKQEHKDVM

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Bovine
100
Chicken
100
Rabbit
100
Pig
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.

PTMs:

Phosphorylated by PKN1.

Subcellular Location:

Cytoplasm.
Note: Associated with intermediate filaments.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in cells lacking fibronectin.

Family&Domains:

Belongs to the intermediate filament family.

Research Fields

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

References

1). NAD+-Boosters Improve Mitochondria Quality Control In Parkinson's Disease Models Via Mitochondrial UPR. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 40685704) [IF=15.1]

Application: WB    Species: Mouse    Sample:

Figure 8 MPTP-induced reactive gliosis and synaptic disruption were attenuated by NMN treatment: a) RT-qPCR analysis revealed that the expression of genes such as Il-1β, II-6, Tnf, Nos2, Ccl2, and Ccl2 (n = 3 independent samples; One-way ANOVA). b–f) Effects of NMN on the expression level of IBA1 and GFAP (n = 3 independent samples; One-way ANOVA). β-actin was used as loading control. g,h,j) Effects of NMN on the expression level of synaptophysin and PSD95 (n = 5 independent samples; One-way ANOVA). β-actin was used as loading control. i,k) Effects of NMN on the expression level of NeuN (n = 6 independent samples; One-way ANOVA). Data are shown as mean ± s.e.m. The P values are indicated on the graphs. NS, not significant.

2). Pharmacological Microglial Inhibition Remodels the Scar Microenvironment to Support Reticulospinal Circuit Reconstruction After Spinal Cord Injury. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 41103249) [IF=15.1]

3). Attenuating α-synuclein pathology in mice with in situ engineered astrocytes. Translational neurodegeneration, 2025 (PubMed: 41261395) [IF=10.8]

4). Neurogenesis promoted by the CD200/CD200R signaling pathway following treadmill exercise enhances post-stroke functional recovery in rats. BRAIN BEHAVIOR AND IMMUNITY, 2019 (PubMed: 31513876) [IF=8.8]

Application: IF/ICC    Species: rat    Sample: astrocytes

Fig. 5.| The expression of CD200 and CD200R was up-regulated induced by treadmill exercise after stroke in rats.The effect of treadmill exercise on the protein levels of CD200 and CD200R in the ischemic cortex (A-C) and hippocampus (D-F) at 7 and 28 days after tMCAO. CD200R staining shows protein expression at 7 and 28 days after treadmill exercise post-stroke (G). CD200R colocalizes with activated microglia (Iba1+cells, white arrows), not colocalizes with neural stem cells (Nestin+ cells) and astrocytes (GFAP+ cells), Scale bar: 50 μm. N = 4. Results are showed as means ± SEM. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the Sham group. *P < 0.05, ** P < 0.01, *** P < 0.001 versus the tMCAO group.

5). Multi-targeted nanogel drug delivery system alleviates neuroinflammation and promotes spinal cord injury repair. Materials today. Bio, 2025 (PubMed: 39935893) [IF=8.7]

6). 3D-Bioprinted Scaffolds with Precise Factor Delivery for Spinal Cord Injury Repair. ACS applied materials & interfaces, 2025 (PubMed: 40673827) [IF=8.3]

7). NAD+-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's disease via ATF4-dependent mitochondrial UPR. Cell death & disease, 2024 (PubMed: 39394148) [IF=8.1]

Application: IF/ICC    Species: Mouse    Sample:

Fig. 5: Cross-species MSR signature attenuates mitochondrial dysfunction. a, c Effects of NMN on the expression level of proteins involved in UPRmt and mitophagy in the 5xFAD mice hippocampi of individuals with and without NMN (n = 3 biologically independent samples; two-sided unpaired t-test). b, d Corresponding quantification of western blot data of (a, c) (n = 3 mice in each group). Data were analyzed by two-sided one-way ANOVA followed by Tukey’s multiple comparisons test. e, f Representative immunostained images (e) and quantification (f) of ATF4 in the hippocampi of AD (VEH) and AD (NMN) tissues (n = 3 mice; two-sided unpaired t-test). Scale bar, 100 μm. g The mRNA expression measurement of MSR signature after supplementing with NMN in 5xFAD mice (n = 3; two-way ANOVA). h Synaptic proteins from the 6-month hippocampi were analyzed by Western blotting (n = 3 mice in each group). Data were analyzed by two-sided one-way ANOVA followed by Tukey’s multiple comparisons test. i–k we obtained T2-weighted anatomical images to analyze the structure difference in the ventricle system using a 9.4 Tesla magnetic resonance imaging (MRI) scanner. Data were pooled from at least 3 biological replicates. Data were analyzed by two-sided one-way ANOVA followed by Tukey’s multiple comparisons test. l Mito-nuclear protein imbalance evaluated by the ratio of mitochondrial DNA (mtDNA)-encoded protein (MTCO1) and nuclear DNA (nDNA)-encoded protein (ATP5a) in three groups (n = 3 mice; one-way ANOVA). m, n Representative immunostaining and quantification of the MitoSOX in the cultured primary astrocytes (n = 6 mice; two-sided unpaired t-test). Scale bar, 20 μm. o, p Representative electron microscopic images, and multiple quantifications, showing the effects of NMN on mitochondrial morphology in mouse hippocampal brain tissues. The quantification was obtained in two independent experiments performed in duplicates in at least 20 ROIs. q ATP Assay was performed in 6-month-old AD mice brain (n = 5 mice, two-sided unpaired t-test). All experiments were performed independently with at least three biological replicates with similar results. Data are shown as mean ± s.e.m. The p-values are indicated on the graphs. ns not significant.

8). Inhibition of abnormal C/EBPβ/α-Syn signaling pathway through activation of Nrf2 ameliorates Parkinson's disease-like pathology. Aging cell, 2023 (PubMed: 37614147) [IF=8.0]

9). Periodic Therapeutic Phlebotomy Mitigates Systemic Aging Phenotypes by Promoting Bone Marrow Function. Aging cell, 2026 (PubMed: 41622984) [IF=8.0]

10). Efficacy and safety of intrathecal human umbilical cord-derived mesenchymal stromal cell therapy for bone cancer pain: a preclinical study. Stem cell research & therapy, 2025 (PubMed: 41276847) [IF=7.5]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.